Avenzo Therapeutics

Avenzo Therapeutics is a clinical-stage biotechnology company specializing in the development of next-generation oncology therapies. The company's primary focus is on treating solid tumors, with a pipeline that includes promising drug candidates for various types of cancer.

Their lead asset, AVZO-021, is a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor. This drug is currently undergoing clinical trials to evaluate its efficacy in treating advanced solid tumors, such as breast cancer, ovarian cancer, and other cancers with cyclin E1 amplification. The development of AVZO-021 is part of a global license agreement with DualityBio.

In addition to AVZO-021, Avenzo is also advancing AVZO-023, a novel CDK4 selective inhibitor. This candidate has received FDA clearance for an Investigational New Drug (IND) application and is being tested in a Phase I/II trial for patients with HR+/HER2- metastatic breast cancer and other solid tumors. The company's business model revolves around identifying and licensing promising oncology assets and advancing them through clinical development. Avenzo has successfully raised significant capital through Series A and A-1 financing rounds, enabling it to fund its pipeline and research activities.

Keywords: oncology, biotechnology, solid tumors, CDK2 inhibitor, CDK4 inhibitor, clinical-stage, cancer therapy, breast cancer, drug development, licensing